Wegovy Side Effects by Percentage: What the Evidence Actually Shows

The myth: most people can't tolerate Wegovy

The most persistent misconception about Wegovy's side-effect profile is that the majority of people suffer badly enough to stop. That's not what the trial data shows. In STEP 1 (the pivotal 68-week study published in the New England Journal of Medicine) nausea was the single most common side effect, reported by around 44% of participants on semaglutide 2.4 mg, compared with 16% in the placebo group. Vomiting occurred in roughly 24% (versus 6% placebo), diarrhoea in about 30% (versus 16%), and constipation in around 24% (versus 11%).

Those numbers look large until you read what they're measuring: any occurrence at any point across 68 weeks. Most events were mild or moderate. Discontinuation because of a side effect affected fewer than 5% of participants on active treatment, a rate that puts Wegovy broadly in line with other medicines in its class. If you've read forum threads suggesting the drug is universally intolerable, the clinical data disagrees.

Timing matters too. Gastrointestinal effects clustered around dose-increase points. The gradual titration schedule (starting low and stepping up roughly every four weeks, guided by the prescriber) is specifically designed to give the gut time to adjust. That graduated approach is not optional. It's the mechanism that keeps the percentages manageable for most people who start.

Which percentages cover more serious effects?

Serious adverse events occurred in 9.8% of participants in the semaglutide arm of STEP 1, versus 6.4% in the placebo group, a meaningful difference, though the absolute rates remain relatively low. The most clinically significant risks to understand before starting are pancreatitis, gallbladder disease, and, in people with pre-existing diabetic eye disease, the possibility of retinopathy complications.

Gallbladder-related events, including gallstones, were reported in roughly 2.6% of semaglutide participants versus 1.2% placebo. Acute pancreatitis was uncommon but present. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as a known, infrequent but potentially serious effect of GLP-1 medicines including semaglutide, reinforcing that providers must screen for pancreatitis history before prescribing.

Heart rate changes (a modest average increase of a few beats per minute) and injection-site reactions were also more common with semaglutide than placebo, though the latter rarely caused discontinuation. On the psychiatric side, adverse events including self-harm ideation were monitored carefully; rates were low and similar between groups, but the prescriber's assessment of mental health history remains a standard part of the eligibility check. The NHS semaglutide medicines page lists effects worth knowing about in plain language and is worth bookmarking once you start.

When to seek medical help, and what to do about it

Numbers are useful. Knowing when to act is more useful. The symptoms below should prompt prompt contact with a medical professional or emergency services, they are not the normal early-GI discomfort that settles within days.

Severe stomach pain that spreads to your back, with or without vomiting, can be a sign of pancreatitis and needs same-day assessment. Yellowing of the skin or eyes, persistent upper-right abdominal pain, or dark urine may indicate gallbladder or liver involvement. Signs of a serious allergic reaction (swelling of the face, lips, tongue or throat, difficulty breathing, or a widespread rash) need emergency attention. Significant dizziness, a very fast heart rate, or sudden vision changes also warrant the same day contact with your GP or NHS 111.

For side effects that concern you but don't feel like emergencies, a quick daily habit worth adopting: check the Patient Information Leaflet inside your pen's box, which lists effects and their expected frequency, it takes under a minute and is more reliable than a search engine. You can also report any suspected side effect directly via the MHRA's Yellow Card scheme, including effects not listed in the leaflet. Yellow Card data is how regulators detect patterns early; it's open to patients as well as healthcare professionals.

If you're wondering whether a symptom you're experiencing is typical, our guide on managing Wegovy side effects covers the practical day-to-day picture. For side effects that seem absent altogether, the explanation of why some people notice very little is worth reading too.

What the percentages can't tell you, and what the consultation can

Population-level statistics describe averages. They can't predict whether you, specifically, will be in the 44% who report nausea or the 56% who don't. Individual risk depends on factors the trial averages over: your existing health conditions, other medicines you take, how you respond to the titration, your diet during treatment, and how well you stay hydrated. These are exactly the things a prescribing clinician weighs before and during treatment.

At nume, a GPhC-registered Independent Prescriber reads your full consultation before any decision is made. There's no algorithm making the call. If the picture is complicated (previous pancreatitis, certain medications, a relevant condition) the prescriber will discuss it with you directly. You can learn more about how Wegovy works as a licensed UK treatment, explore whether it's the right fit via our treatment overview, or look at what broader population data says about who experiences side effects and how often. It's also worth knowing that the effects of treatment aren't limited to digestion, and our page covering how Wegovy can affect your dental health is a useful read before you start.

Side-effect percentages are one part of an informed decision. The consultation is where the rest of the picture comes together. If you want to discuss your own health history with our clinical team, start your free consultation and a prescriber will review your case the same day.